Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367849151> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4367849151 abstract "<div>Abstract<p>Purpose: Patients with metastatic uveal melanoma have limited therapeutic options and high mortality rate so new treatment options are needed. Patients and Methods: We previously reported that patients treated with the PD-1 inhibitor pembrolizumab and the HDAC inhibitor entinostat in the PEMDAC trial, experienced clinical benefits if their tumor originated from iris or was wildtype for BAP1 tumor suppressor gene. Here we present the two-year follow-up of the patients in the PEMDAC trial and identify additional factors that correlate with response or survival. Results: Durable responses were observed in four patients, with additional eight patients exhibiting a stable disease. The median overall survival was 13.7 months. Grade 3 adverse events were reported in 62% of the patients, but they were all manageable. No fatal toxicity was observed. Activity of thymidine kinase 1 in plasma was higher in patients with stable disease or who progressed on treatment, compared to those with partial response. Chemokines and cytokines were analyzed in plasma. Three chemokines were significantly different when comparing patients with and without response. One of the factors, CCL21, was higher in the plasma of responding patients before treatment initiation but decreased in the same patients upon treatment. In tumors, CCL21 was expressed in areas resembling tertiary lymphoid structures (TLS). High plasma levels of CCL21 and presence of TLS-like regions in the tumor correlated with longer survival. Conclusions: This study provides insight into durable responses in the PEMDAC trial, and describes dynamic changes of chemokines and cytokines in the blood of these patients.</p></div>" @default.
- W4367849151 created "2023-05-04" @default.
- W4367849151 creator A5014354451 @default.
- W4367849151 creator A5025004246 @default.
- W4367849151 creator A5026031146 @default.
- W4367849151 creator A5052059834 @default.
- W4367849151 creator A5055595135 @default.
- W4367849151 creator A5056540580 @default.
- W4367849151 creator A5062124149 @default.
- W4367849151 creator A5062578923 @default.
- W4367849151 creator A5067369652 @default.
- W4367849151 creator A5070275752 @default.
- W4367849151 creator A5072335960 @default.
- W4367849151 creator A5073664946 @default.
- W4367849151 creator A5085934310 @default.
- W4367849151 creator A5086298459 @default.
- W4367849151 date "2023-05-03" @default.
- W4367849151 modified "2023-09-24" @default.
- W4367849151 title "Data from Chemokine analysis in patients with metastatic uveal melanoma suggests a role for CCL21 signaling in combined epigenetic therapy and checkpoint immunotherapy" @default.
- W4367849151 doi "https://doi.org/10.1158/2767-9764.c.6628509.v1" @default.
- W4367849151 hasPublicationYear "2023" @default.
- W4367849151 type Work @default.
- W4367849151 citedByCount "0" @default.
- W4367849151 crossrefType "posted-content" @default.
- W4367849151 hasAuthorship W4367849151A5014354451 @default.
- W4367849151 hasAuthorship W4367849151A5025004246 @default.
- W4367849151 hasAuthorship W4367849151A5026031146 @default.
- W4367849151 hasAuthorship W4367849151A5052059834 @default.
- W4367849151 hasAuthorship W4367849151A5055595135 @default.
- W4367849151 hasAuthorship W4367849151A5056540580 @default.
- W4367849151 hasAuthorship W4367849151A5062124149 @default.
- W4367849151 hasAuthorship W4367849151A5062578923 @default.
- W4367849151 hasAuthorship W4367849151A5067369652 @default.
- W4367849151 hasAuthorship W4367849151A5070275752 @default.
- W4367849151 hasAuthorship W4367849151A5072335960 @default.
- W4367849151 hasAuthorship W4367849151A5073664946 @default.
- W4367849151 hasAuthorship W4367849151A5085934310 @default.
- W4367849151 hasAuthorship W4367849151A5086298459 @default.
- W4367849151 hasBestOaLocation W43678491512 @default.
- W4367849151 hasConcept C121608353 @default.
- W4367849151 hasConcept C126322002 @default.
- W4367849151 hasConcept C13373296 @default.
- W4367849151 hasConcept C143998085 @default.
- W4367849151 hasConcept C203014093 @default.
- W4367849151 hasConcept C2776914184 @default.
- W4367849151 hasConcept C2777658100 @default.
- W4367849151 hasConcept C2777701055 @default.
- W4367849151 hasConcept C2780057760 @default.
- W4367849151 hasConcept C502942594 @default.
- W4367849151 hasConcept C71924100 @default.
- W4367849151 hasConceptScore W4367849151C121608353 @default.
- W4367849151 hasConceptScore W4367849151C126322002 @default.
- W4367849151 hasConceptScore W4367849151C13373296 @default.
- W4367849151 hasConceptScore W4367849151C143998085 @default.
- W4367849151 hasConceptScore W4367849151C203014093 @default.
- W4367849151 hasConceptScore W4367849151C2776914184 @default.
- W4367849151 hasConceptScore W4367849151C2777658100 @default.
- W4367849151 hasConceptScore W4367849151C2777701055 @default.
- W4367849151 hasConceptScore W4367849151C2780057760 @default.
- W4367849151 hasConceptScore W4367849151C502942594 @default.
- W4367849151 hasConceptScore W4367849151C71924100 @default.
- W4367849151 hasLocation W43678491511 @default.
- W4367849151 hasLocation W43678491512 @default.
- W4367849151 hasOpenAccess W4367849151 @default.
- W4367849151 hasPrimaryLocation W43678491511 @default.
- W4367849151 hasRelatedWork W2342781363 @default.
- W4367849151 hasRelatedWork W2607780130 @default.
- W4367849151 hasRelatedWork W2777867648 @default.
- W4367849151 hasRelatedWork W2915045061 @default.
- W4367849151 hasRelatedWork W2969782175 @default.
- W4367849151 hasRelatedWork W3153432702 @default.
- W4367849151 hasRelatedWork W3161613553 @default.
- W4367849151 hasRelatedWork W3215044659 @default.
- W4367849151 hasRelatedWork W4292373623 @default.
- W4367849151 hasRelatedWork W4312075079 @default.
- W4367849151 isParatext "false" @default.
- W4367849151 isRetracted "false" @default.
- W4367849151 workType "article" @default.